fotokostic/iStock via Getty Images
Update 9:25pm: Adds details on remedy offered.
Bunge Global (NYSE:BG) offered remedies to the European Union regulators for its planned $8.2 billion purchase of Viterra Inc. as it tries to win antitrust approval for the deal.
Bunge (BG) offered the commitments to the European Commission on Thursday, according to a listing on the regulator’s website. The specific details of the remedies weren’t disclosed.
Bunge offered to sell assets in two European Union countries to try to secure regulatory approval, according to a Reuters report on Friday, which cited people familiar with the matter.
The EC has a deadline of Aug. 1 to decide if it will push the review of the Viterra deal into a more in-depth investigation.
“We are confident that the commitments we have offered address the areas of concern expressed by the Commission, which are limited to specific markets,” a Bunge spokesperson told multiple news outlets including Reuters and Bloomberg.
The EC update comes after a Bloomberg report on Thursday that the transaction is unlikely to be completed by Bunge’s target date at the end of August. Countries including Canada, China and the EC haven’t approved the acquisition.